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Abstract
We conducted a longitudinal study of tobacco use among adults initiating antiretroviral therapy 
(ART) in Mbarara, Uganda where 11% of men and 3% of women use tobacco according to the 
2011 Demographic and Health Survey. In a prospective cohort, self-reported tobacco use was 
assessed before starting ART and reassessed every 3–4 months. Plasma cotinine, a nicotine 
metabolite, was measured in a subset of adults pre-ART to verify self-report. Among 496 subjects, 
50 (10%) reported current tobacco use (20% of men, 6% of women). Most (53%) adults with 
elevated cotinine levels (>15 ng/mL) reported no tobacco use. By 6 months after ART initiation, 
33% of tobacco users had quit (95% CI=20–46%). By 5 years, 64% quit (95% CI=47–77%). Self-
reported tobacco use among rural Ugandans starting ART was twice as common as among the 
local background population and use may be underreported. ART initiation could be an 
opportunity for tobacco cessation interventions.
Keywords
Tobacco use; smoking cessation; socioeconomic status; resource-limited setting; antiretroviral 
treatment initiation
*Corresponding author: 50 Staniford Street, 9th Floor, Boston, MA 02114, Telephone: 617-724-3157, Fax: 617-724-3544, 
gkruse@mgh.harvard.edu. 
An earlier version of this work was presented as a poster at the Society for Research on Nicotine and Tobacco 19th Annual meeting on 
March 16, 2013 in Boston, MA.
Conflicts of Interest: The authors declare no conflicts of interest.
Published in final edited form as:























Tobacco use is a leading cause of preventable death, projected to claim one billion lives in 
the 21st century [1]. Of the six million deaths per year that are attributed to tobacco globally, 
80% occur in resource-limited countries. At the same time, 97% of HIV-infected persons 
live in resource-limited countries. In resource-rich countries in the era of potent 
antiretroviral therapy (ART), people living with HIV have a prevalence of tobacco use that 
is two to three times higher than among people without HIV [2–8] even after accounting for 
sociodemographic characteristics [9]. The high prevalence of smoking among people 
infected with HIV has not been well-studied. It is likely related to multiple factors including 
socioeconomic disadvantage, comorbid substance use disorders, psychiatric disorders, 
physical or mental distress, or health beliefs about living with HIV [10]. High rates of 
tobacco use leads to a high burden of tobacco related illness with an estimated one out of 
four deaths among people with HIV attributable to smoking [11, 12]. In resource-rich 
nations, where coordinated care for HIV and treatments for cancer and cardiovascular 
disease are available, tobacco use accounts for more years of life lost among people with 
HIV than HIV itself [13].
Sub-Saharan Africa (SSA) has relatively low tobacco use prevalence in the general 
population ranging from 8.0% in low prevalence countries to 27.3% in high prevalence 
countries [14, 15]. There are few studies of the prevalence of tobacco use among HIV-
infected individuals in resource-limited settings. When tobacco use has been examined in 
cross-sectional studies, it appears the prevalence of tobacco use among HIV-infected 
individuals is higher than the general population [16–19]. In prevalence studies, tobacco use 
can be measured by self-report or with biochemical measures. Cotinine is a metabolite of 
nicotine that can be measured in the urine, saliva and serum of people exposed to nicotine 
through personal tobacco use, environmental tobacco smoke exposure or use of nicotine 
containing medications. Validation of self-reported tobacco use by cotinine levels from 
resource rich settings shows little underreporting [20–22]. However, the accuracy of self-
report in resource-limited settings has not been well studied.
In contrast to resource-rich settings, people in resource-limited settings may not have access 
to treatments for cardiovascular disease or cancer. The burden of tobacco-related illness 
among tobacco users with HIV may be even greater in these settings. We do not know how 
tobacco use changes over time as patients engage in HIV care and treatment programs in 
resource limited settings. For many people, particularly young people in settings where 
primary care is limited, starting treatment for HIV may be the first sustained interaction they 
have with the healthcare system. Starting treatment is also a time when people may feel 
especially vulnerable with regard to their health. This may be a time when they are 
particularly receptive to health promoting messages like advice to abstain from tobacco. In 
resource rich settings, people with HIV infection are interested in quitting [23], but less 
successful at achieving abstinence from tobacco than smokers without HIV [24]. The 
patterns of tobacco use and cessation among people with HIV infection in resource limited 
settings, where there are few or no treatment services for tobacco cessation, is not known. 
The aim of this study is to measure the prevalence and patterns of tobacco use over time 
among adults initiating treatment for HIV in rural southwest Uganda.
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The Uganda AIDS Rural Treatment Outcomes (UARTO) study is a prospective cohort of 
HIV-infected adults (≥18 years old) who are initiating antiretroviral treatment (ART) at the 
Immune Suppression Syndrome Clinic in Mbarara University of Science and Technology. 
Participants were approached for recruitment if they were ART-naïve, over 18 years of age, 
and lived within 20 miles of the clinic. Other study details have been described in detail 
elsewhere [25]. Mbarara is a rural district in southwestern Uganda, located five hours by 
automobile from Kampala. Current tobacco use in the general population in southwestern 
Uganda is estimated to be 11% in men and 3% in women according to the national 
Demographic and Health Survey in 2011 [26]. We included subjects enrolled in UARTO 
starting in 2005 and followed through 2011. The loss to follow-up rate in the UARTO 
cohort (participants for whom researchers were unable to confirm vital status after 180 days 
without cohort follow-up) was 2% at one year and 5% at two years [27].
Measurements
At both baseline visits and every three to four months at routine follow-up, subjects undergo 
structured interviews and provide blood for routine HIV-related monitoring. Data collected 
prior to ART initiation include demographic traits, household characteristics, and 
socioeconomic measures of educational attainment, monthly income, and occupation. We 
categorized occupation according to groupings defined in other tobacco prevalence studies 
using national demographic and health surveys in Africa [15]. We used the same four 
categories as these prior studies (1) managers, professionals, technicians, sales, and clerical 
workers, (2) household, domestic, service, craftsmen, tradesmen and other manual workers, 
(3) self-employed or informal agricultural workers (including subsistence farmers), or (4) 
unemployed or not working. Educational attainment was categorized as less than primary 
school, completed primary school, or some secondary school or more. Health status was 
assessed by history of HIV with lab results, tuberculosis, and the MOS-HIV summary scores 
for physical and mental health and subscales for social functioning, mental health, and 
health distress [28].
Tobacco use is assessed by self-report by asking participants if they have ever used smoking 
tobacco/cigarettes or chewing tobacco and if they have used these tobacco products in the 
past 30 days. Alcohol use is assessed using the three questions about alcohol consumption 
from the of the Alcohol Use Disorders Identification Test (AUDIT-C) [29]. The AUDIT-C 
has been evaluated as a brief screening test to detect heavy drinking and/or alcohol abuse or 
dependence among primary care patients [30]. Patients who screen positive were considered 
to have problem alcohol use. In our population, an option is added for patients to report they 
are unable to quantify alcohol use due to consuming homemade alcohol. The AUDIT-C was 
not calculated for these patients.
In a subset of patients, baseline plasma samples were tested for cotinine using Salimetrics 
Saliva Cotinine ELISA kit (State College, PA) to confirm self-reported tobacco use. 
Cotinine is a nicotine metabolite measurable among individuals who smoke, use smokeless 
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tobacco, use nicotine products (i.e. nicotine patch, nicotine gum), or are exposed to 
environmental tobacco smoke. The subset was a purposive sample selected as part of an 
analysis of biochemical confirmation of alcohol use [31]. The subset included patients who 
reported alcohol use in the prior year as well as a random sample of patients with no 
reported alcohol use. When cotinine was detectable, levels were repeated for confirmation. 
We used the average of the repeated measures as the cotinine level.
Statistical Analysis
We estimated baseline prevalence of current tobacco use. Current use was defined as self-
reported use of smoked tobacco/cigarettes or chewing tobacco products in the last 30 days at 
time of enrollment. We identified subjects who reported no tobacco use in their lifetime as 
never users at baseline. We identified those who reported any lifetime tobacco use but no 
current use as former users.
Among the subset of patients with baseline plasma cotinine levels, we compared cotinine 
levels by reported tobacco use with the Kruskal-Wallace chi-square test. We further 
measured the accuracy of self-reported tobacco use compared to cotinine level as the gold-
standard indicating current tobacco use. We calculate the sensitivity, specificity, negative 
and positive predictive value of self-reported tobacco use. We used cotinine greater than 15 
ng/mL as the cutpoint for current tobacco use [32]. This is a widely cited cutpoint based on 
data from the United Kingdom in the 1980s. Saliva or plasma cotinine measures at optimal 
cut-points have been measured at 96–97% sensitivity and 99–100% specificity compared to 
known smoking behavior [33]. Lower cutpoints have been recommended for U.S. samples 
based on recent population surveys. This decrease in optimal cotinine cutpoint is attributed 
to decreasing secondhand smoke exposure. These recommendations are further tailored to 
racial differences in cotinine metabolism [34]. Some racial groups and pregnant women 
metabolize cotinine more slowly which leads to longer cotinine half-life. In Uganda, 
however, we opted for the higher 15 ng/mL cutpoint because of reported high rates of 
environmental tobacco exposure [35] more similar to the 1980s U.K. environment than 
current U.S. environmental tobacco exposure.
Baseline associations between current tobacco use and demographic characteristics, 
socioeconomic status, and health status are calculated using log-binomial regression to 
calculate unadjusted and adjusted prevalence ratios. If a model failed to converge, we 
instead used Poisson regression with robust variance estimates to calculate prevalence ratios 
[36]. In multivariable models, we included all variables associated with self-reported 
tobacco use in unadjusted models at p<0.05. We had few missing data (8%) and used 
complete case analysis, excluding subjects missing any model variable. To evaluate for 
violation of the positivity assumption, we cross-tabulated our categorical variables of 
gender, alcohol use, education, and occupation to ensure there were subjects at all categories 
of exposure at every combination of confounders [37].
We used self-reported tobacco use at follow-up to calculate two time to event outcomes. 
First, we measured the time to initiation of tobacco use among never and former tobacco 
users. Time to initiation of tobacco use was calculated as number of days from enrollment to 
the date of the visit when tobacco use was first reported. Tobacco cessation was defined as 
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no tobacco use reported in the last 30 days at two or more consecutive visits. This definition 
has been used in other longitudinal studies of tobacco use [38] and is highly correlated with 
other self-reported tobacco cessation outcomes [39, 40]. Using this definition, we measured 
time to cessation among baseline tobacco users. Time to cessation was calculated as number 
of days from enrollment to the first of the two consecutive visits with no reported tobacco 
use. If tobacco use status was not documented at a visit, the status from the prior visit was 
used. Subjects who did not start or stop tobacco use were censored at their last study visit.
We compared time to initial use or time to cessation using cumulative incidence functions 
[41]. We considered death a competing event. Cumulative incidence functions were 
compared by gender, alcohol use, and socioeconomic status. We used Gray’s test for 
equality of cumulative incident functions to compare differences in time to event between 
groups [42].
All analyses were conducted using SAS version 9.3 (Cary, NC). UARTO’s procedures were 
approved by ethical review boards at the University of California at San Francisco, Partners 
HealthCare, and Mbarara University of Science and Technology. All subjects gave informed 
consent to participate in the study.
RESULTS
Among 508 ART-naïve adults who were enrolled in the cohort during the analysis period, 
503 completed baseline interviews. This includes 496 who provided information about their 
cigarette/smoked tobacco or chewing tobacco use that comprises our study sample. The 
population was mostly female (69%), with a median age of 35 years (interquartile range 
[IQR]: 29–40, Table I). More than one-half (51%) were married, 23% completed primary 
school, and 26% completed secondary school or more. The most common occupational class 
was non-manual workers (professionals, managers, technicians, sales and clerical workers) 
who comprised 30% of the sample. Another 28.4% were informal agricultural workers or 
self-employed (including subsistence farmers), 16.3% were household, domestic, service, 
craftsmen, tradesmen and other manual workers and 25.2% reported unemployment. The 
median income was 40,000 Ugandan schillings, or approximately US$16, (IQR 15,000–
95,000). Almost one-half (48%) reported fair or poor health, 11% had a prior history of 
tuberculosis, 22% screened positive for alcohol use problems, and the median CD4+ T-cell 
count was 133 cells/mm3 (IQR 76–201 cells/mm3).
In this group, 20% of men and 6% of women reported tobacco use in the 30 days prior to 
starting treatment with ART. The vast majority of tobacco use was smoked tobacco 
products/cigarettes (90%, N=45). Only four (8%) patients used chewing tobacco and one 
(2%) used both cigarettes/smoked tobacco and chewing tobacco products. Former tobacco 
use was reported among 75 adults including 69 people who had previously smoked tobacco 
or cigarettes, three who had previously used chewing tobacco, and three who had used both 
smoking and chewing tobacco.
In our subset of patients with baseline cotinine (the nicotine metabolite) measurements 
(N=128), the median cotinine level for patients who reported tobacco use in the past 30 days 
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was 580.3 ng/mL (IQR 205.7–1140.1 ng/mL) compared to 10.0 ng/mL (IQR 6.0–10.0 
ng/mL) among those who reported no baseline tobacco use (Kruskal-Wallis χ2 29.82, 
p<0.001). Cotinine was above our cutpoint of 15 ng/mL for current tobacco use in 27% of 
samples (Table II). This includes 11% of never users (N=9/80), 32% of former tobacco users 
(N=10/31), and 88% of current tobacco users (N=15/17) (Pearson χ2 43.29, p<0.001). Self-
report of current (past 30-day) tobacco use had a sensitivity of 44% and a specificity of 98% 
compared to plasma cotinine >15 ng/mL as the measure of biochemically-confirmed tobacco 
use. The median cotinine level among our 19 false negative tobacco users—those who 
reported no tobacco use in the past 30 days but who had elevated cotinine levels >15 ng/
mL)--was 286.3 ng/mL (IQR 154.3–379.1 ng/mL). The positive predictive value of self-
report of tobacco use was 88% and the negative predictive value of reporting no tobacco use 
was 83%.
In unadjusted models examining the predictors of self-reported tobacco use prior to starting 
ART we included 456 subjects with no missing independent variables in the models. This 
included 45 current tobacco users. Marital status, income, general health, physical health, 
mental health, social functioning, and health distress were not associated with tobacco use 
(Table III). Being older, male, reporting problem alcohol use, and having less education 
were positively associated with tobacco use. By occupational status, self-employment/
informal agricultural workers and being employed as a manual worker (household, 
domestic, service, craftsmen, tradesmen and other manual workers), compared to those who 
were unemployed, were also positively associated with tobacco use.
We included 456 subjects with no missing data in our multivariable log-binomial regression 
model. Forty-five of these patients were current tobacco users. Age, gender, occupation, 
education, and problem alcohol use met our criteria for inclusion. A cross-tabulation of these 
categorical covariates had empty cells for women in the highest education category and men 
in the second highest education category. To prevent violation of the positivity assumption, 
we combined the two highest educational categories for the multivariable model. Male 
gender, problem alcohol use, employment as manual worker (household, domestic, service, 
craftsmen, tradesmen and other manual workers), and less education were independently 
associated with tobacco use.
Our longitudinal data included 453 patients with one or more follow-up visits. The median 
follow-up time from date of enrollment to date of last visit was 3.7 years (Range: 0.2–5.9; 
IQR 2.5–4.4). Thirty-eight patients died including one tobacco user, two former users who 
restarted during follow-up, and 35 never users. Initial tobacco use was reported among six of 
340 adults with no prior tobacco use. Another seven of the 67 former tobacco users reported 
resuming tobacco use during follow-up. Initial tobacco use was higher among men 
compared to women (cumulative incidence function [CIF] at five years, 0.08, 95% 
confidence interval [CI] 0.04–0.15 vs. CIF 0.02, 95% CI 0.01–0.04, Gray’s test for equality 
of CIF χ2=8.58, p=0.004, Figure 1) and former tobacco users compared to never users (CIF 
0.10, 95% CI 0.04–0.18 vs. CIF 0.02, 95% CI 0.01–0.05, Gray’s test for equality of CIF 
χ2=8.23, p=0.004).
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Among 46 baseline tobacco users seen in follow-up, 28 reported no tobacco use for two 
consecutive visits. The cumulative incidence of quitting among baseline tobacco users was 
0.64 by 5 years (95% CI=0.47–0.77) with one-third quitting in the first six months after 
follow-up (cumulative incidence at 6 months: 0.33, 95% CI: 0.20–0.46). Nine patients made 
two or more attempts before quitting. We did not detect a difference in tobacco cessation by 
gender (Figure 2), alcohol use, education, or occupation.
DISCUSSION
In this resource-limited setting, tobacco use was roughly twice as common among people 
with HIV as among the population in general. In the Southwest region of Uganda, according 
to the most recent Ugandan national Demographic and Health Survey, 3% of women and 
11% of men aged 15–49 use tobacco [26]. In our population of HIV-infected adults who 
were initiating ART, we found that 6% of women and 20% of men with HIV were currently 
using tobacco. This relatively high self-reported tobacco use is similar to that found in 
resource-rich settings where people with HIV infection are two to three times more likely to 
use tobacco than people without HIV [2–4, 24, 43]. Additionally, biochemical verification 
of tobacco use with a nicotine metabolite suggests that tobacco use is underreported in this 
setting.
Managing traditional risk factors for cardiovascular disease [44] and malignancy [45], like 
tobacco use, could greatly impact morbidity and mortality among people infected with HIV. 
Therefore, even in this low prevalence setting, tobacco use is an important risk factor that 
should be assessed among every patient. The impact of tobacco cessation may be greater in 
resource-limited regions where secondary and tertiary treatment services are largely 
unavailable than in resource-rich settings.
Our finding that higher rates of tobacco use are concentrated among adults with manual 
labor jobs and lower educational attainment is consistent with prior work in SSA [19] as 
well as resource rich settings. Efforts to promote cessation should be targeted toward these 
groups.
The large proportion of patients who quit after initiating ART suggest that initial 
engagement in healthcare services may be an important time to promote cessation. In other 
regions of SSA, where tobacco use is more common, the majority of tobacco users in HIV 
care report receiving advice to quit [46]. Subjects in this study may be particularly interested 
in improving their health, as evidenced by staring treatment and engaging in HIV care. They 
may therefore be particularly receptive to health promoting advice. Capitalizing on this 
opportunity to deliver evidence-based tobacco cessation counseling might yield large effects 
on smoking cessation. Further reducing tobacco use among people infected with HIV could 
impact morbidity and mortality of patients in HIV care and treatment programs.
We acknowledge several limitations in our study. First, although self-reported tobacco use 
has been shown to correlate highly with cotinine levels in other settings [21], we found 
underreporting of tobacco use at baseline. There may also have been underreporting in 
follow-up and this could have contributed to the high cessation rate. We do not have data on 
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cotinine levels at follow-up to assess potential underreporting at that point. We do not know 
if social pressures to underreport increase as patients engage in treatment or decrease as they 
become more comfortable with their providers. Therefore we do not know how 
misrepresentation of tobacco use changes over time. More work is needed to understand the 
social desirability and stigma associated with reporting tobacco use in SSA and other 
resource poor settings.
Second, in defining cessation, we relied on a measure of use in the last 30 days. It may be 
that many tobacco users are not daily smokers, they use tobacco only very intermittently and 
we cannot definitively distinguish these intermittent users from those who smoke regularly 
and then quit. However, the mean cotinine of self-reported smokers is at least consistent 
with daily smoking patterns with cotinine of 694 ng/mL which is well above levels typically 
seen in daily smoker (e.g. 300 ng/mL) [33]. We did not detect a difference in cessation over 
time among our self-reported smokers by demographic or socioeconomic characteristics. We 
may have been underpowered to compare these groups. Finally, we did not have information 
about tobacco use patterns such as quantity and frequency of use. Prior studies suggest 
quantity smoked is relatively low in SSA ranging from only four to eight cigarettes per day 
on average [15, 19]. This information is important to understand the impact of tobacco use 
in this population and to help design tobacco cessation interventions.
In conclusion, 20% of men and 6% of women initiating treatment for HIV report current 
tobacco use in a region where there is little tobacco use in the general population. Tobacco 
use is a modifiable risk factor for cardiovascular disease and cancer among people with HIV 
which could threaten the ongoing success of HIV care and treatment programs in resource-
limited settings. Tobacco use also disproportionately affects patients with low 
socioeconomic status. Engagement in care at the time of HIV treatment initiation offers an 
opportunity to address tobacco and this should be explored and leveraged to further reduce 
tobacco use in this population.
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Table I
Baseline characteristics of UARTO cohort
Total N %
DEMOGRAPHICS
Age (median, IQR) 496 35 29–40
Gender 496
 Male 154 31.1
 Female 342 68.9
SOCIOECONOMIC STATUS
Marital status 496
 Married and living together 251 50.6
 Widowed 110 22.2
 Divorced/single/separated 135 27.2
Education 467
 Did not complete primary school 238 51.0
 Completed primary school 109 23.3
 Secondary school or more 120 25.7
Occupation (4 class) 496
 Managers, professionals, technicians, sales, and clerical workers 149 30.0
 Household, domestic, service, craftsmen, tradesmen and other manual workers 81 16.3
 Informal or self-employment including subsistence farming 141 28.4
 Unemployed 125 25.2
Household monthly income (Ugandan shilling) (median, IQR) 332 40,000a 15,000–95,000
 Missing household income 164 33.1
HEALTH STATUS
Overall health 483
 Excellent 20 4.1
 Very good 57 11.8
 Good 151 31.3
 Fair 189 39.1
 Poor 66 13.7
MOS-HIV 470
 Social functioning (median, IQR) 100 80–100
 Mental health (median, IQR) 76 60–92
 Health distress (median, IQR) 95 75–100
 Physical health summary score (median, IQR) 53 44–58
 Mental health summary score (median, IQR) 52 45–57
History of tuberculosis 496 54 10.9
Baseline CD4 (median, IQR) 496 133 76–201
SUBSTANCE USE
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Total N %
Problem alcohol use (AUDITC) 483 105 21.7
Current tobacco smoker 496 46 9.3
Current chewing tobacco user 496 5 1.0
Former chewing tobacco user 496 6 1.2
Former tobacco smoker 496 72 14.5
Abbreviations: UARTO, Uganda AIDS Rural Treatment Outcomes study; IQR, interquartile range; AUDIT-C, Alcohol Use Disorders 
Identification Test; MOS-HIV, Medical Outcomes Study HIV Health Survey.
a
40,000 Uganda Shillings is approximately equal to US$16.
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Table II
Validation of self-reported tobacco use at baseline
Cotinine>15 ng/mL
N (row %) [col %]
Cotinine≤ 15 ng/mL
N (row %) [col %]
TOTAL
Reported tobacco use 15 (88%) [44%] 2 (12%) [2%] 17 (13%)
No reported tobacco use 19 (17%) [56%] 92 (83%) [98%] 111 (87%)
TOTAL 34 (27%) 91 (71%) 128
Sensitivity of self-reported tobacco use=44%
Specificity of self-reported tobacco use=98%
Positive predictive value of self-reported tobacco use=88%
Negative predictive value of no self-reported tobacco use=83%
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